Epizyme prices IPO at $15, the high end of the range

By
A A A

Epizyme, a biotech developing therapeutics for patients with genetically defined cancers, raised $77 million by offering 5.1 million shares at $15, the high end of the range of $13 to $15. Epizyme plans to list on the NASDAQ under the symbol EPZM. Epizyme initially filed confidentially on 3/22/2013. Citi, Cowen & Company and Leerink Swann acted as lead managers on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks: EPZM

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

What to Wear to a Wedding
What to Wear to a Wedding           
4th of July Outfits
4th of July Outfits                 

Stocks

Referenced

Most Active by Volume

62,287,287
  • $17.03 ▼ 1.10%
26,194,993
  • $30.555 ▲ 1.24%
26,150,957
  • $126.44 ▼ 0.13%
25,197,634
  • $40.59 ▼ 6.26%
25,192,083
  • $19.07 ▲ 1.54%
24,563,617
  • $26.78 ▲ 0.45%
24,474,256
  • $5.85 ▲ 1.56%
24,111,132
  • $8.83 ▲ 2.08%
As of 7/2/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com